Open-label assessment of the long-term tolerability, safety, and efficacy of sertindole in patients with schizophrenia

被引：0
|
作者：
Hale, T. [1 ]
Murray, R. M. [1 ]
Azorin, J. M. [1 ]
Maehlum, E. [1 ]
机构：
[1] St Martins Hosp, Canterbury, Kent, England
来源：
SCHIZOPHRENIA BULLETIN | 2007年 / 33卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
引用
收藏
页码：431 / 432
页数：2
相关论文
共 50 条
  • [31] Long-term safety and tolerability of lacosamide monotherapy in patients with epilepsy: Results from a multicenter, open-label trial
    Ben-Menachem, Elinor
    Dominguez, Jacqueline
    Szasz, Jozsef
    Beller, Cynthia
    Howerton, Charles
    Jensen, Lori
    McClung, Carrie
    Roebling, Robert
    Steiniger-Brach, Bjorn
    EPILEPSIA OPEN, 2021, 6 (03) : 618 - 623
  • [32] An open-label, long-term study examining the safety and tolerability of pregabalin in Japanese patients with central neuropathic pain
    Onouchi, Kenji
    Koga, Hiroaki
    Yokoyama, Kazumasa
    Yoshiyama, Tamotsu
    JOURNAL OF PAIN RESEARCH, 2014, 7 : 439 - 447
  • [33] Safety and Tolerability of Plecanatide in Patients with Chronic Idiopathic Constipation: Long-term Evidence from an Open-Label Study
    De La Portilla, Marianela
    Barrow, Laura
    Hickey, Bernadette
    Griffin, Patrick
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 : S248 - S249
  • [34] Evaluation of long-term efficacy and tolerability of irbesartan in elderly hypertensive patients with renal impairment in an open-label study
    De Rosa, ML
    Cardace, P
    Rossi, M
    Baiano, A
    de Cristofaro, A
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2002, 63 (03): : 201 - 215
  • [35] Long-term Efficacy and Tolerability of RPC4046 in an Open-Label Extension Trial of Patients With Eosinophilic Esophagitis
    Dellon, Evan S.
    Collins, Margaret H.
    Rothenberg, Marc E.
    Assouline-Dayan, Yehudith
    Evans, Larry
    Gupta, Sandeep
    Schoepfer, Alain
    Straumann, Alex
    Safroneeva, Ekaterina
    Rodriguez, Cristian
    Minton, Neil
    Hua, Steven Y.
    Hirano, Ikuo
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2021, 19 (03) : 473 - +
  • [36] Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson's disease psychosis
    Ballard, Clive G.
    Kreitzman, David L.
    Isaacson, Stuart
    Liu, I-Yuan
    Norton, James C.
    Demos, George
    Fernandez, Hubert H.
    Ilic, Tihomir V.
    Azulay, Jean-Philippe
    Ferreira, Joaquim J.
    Abler, Victor
    Stankovic, Srdjan
    PARKINSONISM & RELATED DISORDERS, 2020, 77 : 100 - 106
  • [37] Long-term Evaluation of Open-label Pimavanserin Safety and Tolerability in Parkinson's Disease Psychosis
    Ballard, Clive
    Kreitzman, David
    Isaacson, Stuart
    Norton, James
    Demos, George
    Liu, I-Yuan
    Fernandez, Hubert
    Ilic, Tihomir
    Azulay, Jean
    Ferreira, Joaquim
    Abler, Victor
    Stankovic, Srdjan
    NEUROLOGY, 2020, 94 (15)
  • [38] Long-Term Safety and Efficacy of Open-Label Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis
    Deleuran, Mette
    Thaci, Diamant
    Beck, Lisa A.
    Forman, Seth
    Soong, Weily
    Hussain, Iftikhar
    Bissonnette, Robert
    Bouaziz, Jean-David
    Gelfand, Joel
    Sher, Lawrence
    Chen, Zhen
    Akinlade, Bolanle
    Gadkari, Abhijit
    Eckert, Laurent
    Graham, Neil M. H.
    Pirozzi, Gianluca
    Ardeleanu, Marius
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2017, 139 (02) : AB381 - AB381
  • [39] Long-term efficacy and safety during open-label erenumab treatment in Japanese patients with episodic migraine
    Sakai, Fumihiko
    Takeshima, Takao
    Tatsuoka, Yoshihisa
    Hirata, Koichi
    Cheng, Sunfa
    Numachi, Yotaro
    Peng, Cheng
    Xue, Fei
    Mikol, Daniel D.
    HEADACHE, 2021, 61 (04): : 653 - 661
  • [40] Long-Term Safety and Efficacy of Olokizumab in Patients with Rheumatoid Arthritis - Results of an Open-Label Extension Study
    Feist, Eugen
    Nasonov, Evgeny
    Luggen, Michael
    Fatenejad, Saeed
    Grishin, Sergey
    Samsonov, Mikhail
    Fleischmann, Roy
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 603 - 606
12345